Smiths Detection launches new automatic object recognition software - iCMORE Prohibited Items
Smiths Detection, a global leader in threat detection and security screening technologies, today announces that it has launched its latest automated detection algorithm, iCMORE Prohibited Items. iCMORE Prohibited Items is the latest addition to Smiths Detection’s family of smart and adaptable automatic object recognition algorithms. The software has been targeted to achieve the European Civil Aviation Conference’s (ECAC) new Automated Prohibited Items Detection Systems (APIDS) certification.
iCMORE Prohibited Items uses artificial intelligence-based algorithms to automatically detect items determined to be a security risk at airport security checkpoints such as firearms, knives, scissors, axes, grenades, blasting caps, ammunition and blunt objects. With certification, such algorithms could lead to a more automated screening process which would enable alarm-only viewing of X-ray images at airport passenger checkpoints. Alarm only viewing has been successfully used in airport hold baggage screening for years, considerably reducing the number of images needing to be viewed manually by an operator, helping to speed up screening time.
The manual review process by an operator can be further improved by using remote screening or Centralized Image Processing (CIP), which utilises a single location for the screening and analysing of X-ray images from multiple systems in different locations.
In light of the severe staff shortages and increasing passenger numbers that airports have to face, this will be a key enabler for increased operational efficiency, throughput and security while also reducing operational expenditure and facilitating resource planning.
When used at non-regulated people checkpoints, the additional detection capabilities of iCMORE Prohibited Items provides invaluable support to image analysts by automatically highlighting threats for further analysis, helping to improve security outcomes. Requiring minimal training and as iCMORE has an intuitive interface it is easy to use, leading to immediate results.
iCMORE Prohibited Items will initially be available for use with Smiths Detection’s market leading Computer Tomography (CT) passenger checkpoint scanner the Hi-SCAN 6040 CTiX. The algorithm will then launch across additional dual-view and multi-view checkpoint systems over the coming months, both, for regulated and unregulated markets. CT will remain the most efficient, flexible and future-proof X-ray technology to handle alarm-only viewing.
Global Director Digital Market Smiths Detection, Cymoril Métivier, said: “iCMORE Prohibited Items is the latest in our suite of advanced detection algorithms designed to help our customers achieve their security and operational goals. With the well documented staffing pressures and increasing passenger numbers at airports, iCMORE Prohibited Items will be a key enabler for increased operational efficiency and throughput, while also reducing operational expenditure and facilitating resource planning.”
About the iCMORE:
iCMORE is a family of automatic target recognition applications. The object recognition software, iCMORE, uses advanced algorithms to reduce the burden on operators – and potential errors – by automating the detection process for suspicious items within inspected cargo, baggage or palleted goods.
About Smiths Detection:
Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 70 years of field-tested experience, Smiths Detection deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals, biological agents, and narcotics – helping make the world a safer place.
For more information visit http://www.smithsdetection.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005182/en/
Contact information
Media:
FTI Consulting:
Tom Hufton/Harriet Jackson/Ffion Dash
sc.smithsdetection@fticonsulting.com
+44 (0)20 3727 1000
Smiths Detection:
Sophie Mills, Head of Corporate Communications
sophie.mills@smithsdetection.com
+ 44 (0)73 8423 6474
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
